Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis

Journal article

Introduction. Guselkumab (Tremfya®) is an injectable solution used to treat moderate to severe psoriasis and is recommended for patients who are candidates for systemic treatment or phototherapy [1]. It is an immunosuppressive medication that acts on the cytokine IL-23, involved in the regulation of the inflammatory response [2]. Being a new medication, there is an opportunity to carry out a review without bias, in addition to exposing those present in the selected articles. Goal.  To analyze...

Expand abstract

Authors: Strober, B; Coates, LC; Lebwohl, MG; Deodhar, A; Leibowitz, E

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Springer
• Journal: Drug Safety: The Official Journal of the International Society of Pharmacovigilance
• Volume: 47
• Issue: 1
• Pages: 39-57
• Publication date: 2023-10-31
• DOI: 10.1007/s40264-023-01361-w
• EISSN: 1179-1942
• ISSN: 0114-5916
• Language: Portuguese
• Keywords: Incidence (geometry); Adverse effect; Placebo; Psoriasis; Population; Concomitant; Pathology; Medicine; Body surface area; Psoriatic arthritis; Psoriasis Area and Severity Index; Dermatology; Internal medicine